INDIANAPOLIS, May 29, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions in San Francisco, California. Remarks will focus primarily on results from the REWIND study of Trulicity, as well as Phase 2 data being presented for tirzepatide, Lilly's dual GIP/GLP-1 receptor agonist. The webcast will begin at 10:00 a.m. Eastern Time, or 7:00 a.m. Pacific Time.
Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm. A replay will also be available on the website following the conference call.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. F-LLY
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-discuss-ada-presentations-and-diabetes-portfolio-300858568.html